| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
,1
* EuroMISE Center-Cardio and Institute of Hygienic Medicine and Epidemiology, and
4th Department of Internal Medicine and Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty, Charles University, Prague, Czech Republic
Abstract
Bilirubin, a major intravascular product of heme catabolism, is a potent antioxidant compound. Numerous studies have been published showing the relationship between serum bilirubin levels and atherosclerosis. In the present investigation all the epidemiological studies available on the effect of serum bilirubin levels and atherosclerotic disease were analyzed. Studies on the epidemiology of atherosclerotic diseases in relation to serum bilirubin levels were searched in the MEDLINE database. Selected studies were subdivided according to serum bilirubin levels and severity of atherosclerotic disease. Because of the limited number of females involved in the studies, only males were included into meta-analysis. Associations for ordered categorical variables (bilirubin and natural history of graded atherosclerosis) were assessed to find correlation and linear trend between analyzed variables. A stratified analysis was conducted to compare risks of clinical outcomes. Eleven relevant studies were used for analysis. A close negative relationship was found between serum bilirubin levels and severity of atherosclerosis (Spearman rank coefficient r = -0.31,P < 0.0001). The linear trend was confirmed in analysis of proportions with x2 values for both disease conditions to be very significant (P < 0.0001). Unambiguous inverse relationship between serum bilirubin levels and atherosclerosis was demonstrated in this preliminary meta-analytic study. These results indicate the importance of hem oxygenase-related products in the prevention of oxidative stress-mediated diseases.
Key Words: atherosclerosis • oxidative stress • ischemia • artery disease
Bilirubin, a major intravascular catabolic product of heme catabolism, is a compound with potent antioxidant capacity. Several clinical epidemiological studies have been published showing the relationship between serum bilirubin levels and oxidative stress-mediated diseases, including in particular atherosclerotic disease (1–11). Although conclusions of the majority of the studies published were rather convincing and suggested important cardiovascular protection from elevated serum bilirubin levels (1, 2, 4–9, 11), this was not the case in all studies (3, 10). Another important limitation was that the designs of the studies were different from each other and also populations studied were stratified according to different serum bilirubin concentrations. In some studies patients with isolated hyperbilirubinemia were not separated from those suffering from apparent liver disease which might have important misleading effect.
In the present investigation we have surveyed all the observational epidemiological studies available dealing with the effect of serum bilirubin levels and both coronary heart and peripheral artery disease. The aim of this study was to bring convincing evidence about the effects of serum bilirubin concentrations on cardiovascular health.
Methods
Studies on the epidemiology of atherosclerotic diseases in relation to the serum bilirubin levels were searched in MEDLINE database. Eleven relevant studies (1–11) were used for analysis (Table I
). Some data required for the analysis were calculated from original graphs and papers. Due to limited numbers of females involved in the studies only males were included into meta-analysis. Three analytical approaches were used: Analysis A of the association of bilirubin levels categorized using Schwertner et al.’s scheme (1) and distributions shifting according to health status classification from true healthy across subclinical to clinical disease was assessed by Spearman rank correlation. In an analysis B, the effects of serum bilirubin levels (i.e., bilirubin specific OR/mean study OR) on atherosclerotic outcome were plotted against serum bilirubin that resulted in the regression line (Fig. 1). Analysis C was performed to estimate common effects of contrasted dichotomous bilirubin levels on cardiovascular disease (Table II). Effects were tested for homogeneity in their orientation and magnitude.
|
|
|
Analysis A.
A close negative relationship was found between ordered serum bilirubin levels and severity of atherosclerosis (Spearman correlation coefficient, r = -0.31, t = -39.94, P < 0.0001) indicating shift of distributions from higher serum bilirubin and better health to lower serum bilirubin and atherosclerotic condition.
Analysis B.
Data in Figure 1
clearly demonstrate strong negative linear association between estimated effects on atherosclerosis and logarithmic scale of serum bilirubin levels supporting results from the study A. As a whole, 34% variability of the effects is explained by bilirubin levels as noted in the result of regression (Fig. 1). Serum bilirubin level of 10 µmol/l is an apparent cut-point for discrimination of cardiovascular risk.
Analysis C.
The seven studies included provided data for stratified analysis (Table II) that further confirmed significant association between bilirubin levels and atherosclerotic outcomes. Because Analysis A and B were focused on categorized although whole bilirubin concentration range, Analysis C is restricted on only two utmost bilirubin level exposure. Common rate ratio (RR) for the prospective studies was 0.79 (95% CI 0.67, 0.90) and for the studies with case-control design common odds ratio (OR) of 0.40 (95% CI 0.29, 0.54) was determined. Both analyzed groups did not show heterogeneity in estimated effects, but heterogeneity existed between follow-up and case-control studies because of different effect of the study designs. In addition, this difference is in magnitude and not in qualitative orientation of the parameters.
Discussion
Based on in vitro as well as animal studies bilirubin is generally recognized as an important antioxidant substance. This is supported also by the majority of clinical studies focused on the protective effect of serum bilirubin levels on atherosclerosis (1, 2, 4–9, 11). However, other studies did not either confirm this relationship (10), or found more pronounced effect in the highest bilirubin levels (3, 4, 9, 10). This can be clearly shown from the OR column in Table I. There are several possible reasons for this observation. Most importantly, the presence of concomitant liver disease was not excluded in the hyperbilirubinemic subjects as can be demonstrated in Figure when re-analyzing data of Breimer and colleagues (3). After dichotomization of top Breime
s bilirubin category the hyperbilirubinemic group subdivide according to the presence of atherosclerosis to a high prevalent subgroup in case of hepatopathy and to that with a very low occurrence in persons without liver disease. Very important is also a manner of bilirubin level scaling. It seems that SI units (µmol/l) are more informative and better discriminate serum bilirubin levels within physiological range than those expressed in mg/dl. Wrong stratification of the study groups according to the serum bilirubin level can negatively influence the overall results of the epidemiological study (10).
All the three types analyses (nonparametric [A], regression [B], and stratified [C]) reliably demonstrate inverse and dose–response relationship between serum bilirubin levels and atherosclerotic process from subclinical to clinical outcomes in this preliminary meta-analytic study.
We are standing at the beginning of the serious assessment of the bilirubin effects for clinical medicine. Further studies carefully designed in particular to the main confounders such as hepatopathy and states of exaggerated consumption of endogenous antioxidants (e.g., smoking) are certainly needed to bring definite evidence for the importance of heme oxygenase-related products in the prevention of oxidative stress-mediated diseases.
Footnotes
This work was supported by the Czech Ministry of Education Grants J 13/98:111100002 and LN 00B107.
1 To whom requests for reprints should be addressed at 4th Dept. Int. Med., 1st Medical Faculty, Charles University, Prague U Nemocnice 2 Praha 2, 128 08 Czech Republic. E-mail: vitek{at}cesnet.cz 
References
ek Z, Danzig V, Novotn L, Kotal P. Gilbert syndrome and ischemic heart disease: A protective effect of elevated bilirubin levels. Atherosclerosis 160:449–456, 2002.[Medline]
This article has been cited by other articles:
|
|
 |
|
  A Sena, R Pedrosa, V Ferret-Sena, M. Cascais, R Roque, C Araujo, and R Couderc Interferon {beta} therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 857 - 859. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Rantner, B. Kollerits, M. Anderwald-Stadler, P. Klein-Weigel, I. Gruber, A. Gehringer, M. Haak, M. Schnapka-Kopf, G. Fraedrich, and F. Kronenberg Association between the UGT1A1 TA-Repeat Polymorphism and Bilirubin Concentration in Patients with Intermittent Claudication: Results from the CAVASIC Study Clin. Chem., May 1, 2008; 54(5): 851 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Perlstein, R. L. Pande, J. A. Beckman, and M. A. Creager Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004 Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Sedlak and S. H. Snyder Messenger Molecules and Cell Death: Therapeutic Implications JAMA, January 4, 2006; 295(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gullu, D. Erdogan, D. Tok, S. Topcu, M. Caliskan, T. Ulus, and H. Muderrisoglu High Serum Bilirubin Concentrations Preserve Coronary Flow Reserve and Coronary Microvascular Functions Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2289 - 2294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ollinger, M. Bilban, A. Erat, A. Froio, J. McDaid, S. Tyagi, E. Csizmadia, A. V. Graca-Souza, A. Liloia, M. P. Soares, et al. Bilirubin: A Natural Inhibitor of Vascular Smooth Muscle Cell Proliferation Circulation, August 16, 2005; 112(7): 1030 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Bach Heme oxygenase-1: a therapeutic amplification funnel FASEB J, August 1, 2005; 19(10): 1216 - 1219. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pflueger, A. J. Croatt, T. E. Peterson, L. A. Smith, L. V. d'Uscio, Z. S. Katusic, and K. A. Nath The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II Am J Physiol Renal Physiol, March 1, 2005; 288(3): F552 - F558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kapitulnik Bilirubin: An Endogenous Product of Heme Degradation with Both Cytotoxic and Cytoprotective Properties Mol. Pharmacol., October 1, 2004; 66(4): 773 - 779. [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Sedlak and S. H. Snyder Bilirubin Benefits: Cellular Protection by a Biliverdin Reductase Antioxidant Cycle Pediatrics, June 1, 2004; 113(6): 1776 - 1782. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Schwertner Bilirubin Concentration, UGT1A1*28 Polymorphism, and Coronary Artery Disease Clin. Chem., July 1, 2003; 49(7): 1039 - 1040. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
